OCM
BLUE

Orser Capital Management’s bluebird bio BLUE Stock Holding History

Orser Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-90
Closed -$203K – 92
2018
Q1 		$203K Buy
+90
New +$229K 0.19% 93

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Orser Capital Management's BLUE Position: Q2 2018 in Review

Orser Capital Management sold out of bluebird bio (BLUE) in Q2 2018, closing a stake of 90 shares — an estimated $203K sold.

Orser Capital Management first reported a position in BLUE in Q1 2018 and held it in 1 quarter. The position peaked at $203K in Q1 2018. 307 funds tracked by Wall St. Rank hold BLUE as of Q2 2018.

  • Orser Capital Management reported no remaining bluebird bio position as of Q2 2018 after selling out during the quarter.
  • Orser Capital Management sold 90 bluebird bio shares in Q2 2018, an estimated $203K.
  • Orser Capital Management first reported a position in bluebird bio in Q1 2018 and held it in 1 quarter.
  • Orser Capital Management's bluebird bio position peaked at $203K in Q1 2018.
  • 307 funds tracked by Wall St. Rank held bluebird bio as of Q2 2018.

Based on Orser Capital Management's 13F filing for Q2 2018, filed 14 Nov 2019.